3 million USD of Calypte Biomedical stock bought by BVI and Panama investors
3 million of Calypte Biomedical stock were bought by 2 investors on June 19, 2006.
Calypte is a company dealing with the development and commercialization of diagnostic testing products detecting sexually transmitted diseases. It's market capitalization is 37 million USD and only 12 employees are working for this corporation. Main direct competitors are global players - Abbott Laboratories and Johnson&Johnson, companies with market capitalisation measured in billions.
The new investors are BVI-based Tanfield International Ltd. and Panama-based International Credit Bank. These corporations decided to purchase 16,666,666 shares of the common stock of Lake Oswego-based Calypte Biomedical, par value 3 cents, at a price 18 cents per share. Currently, the shares are sold at 21 cents per share.
In recent time, the future of Calypte Biomedical was undefined. In February, the American Stock Exchange intended to delist the company's stock. Now, the situation changed as the company raised 3 million USD.
Calypte is a company dealing with the development and commercialization of diagnostic testing products detecting sexually transmitted diseases. It's market capitalization is 37 million USD and only 12 employees are working for this corporation. Main direct competitors are global players - Abbott Laboratories and Johnson&Johnson, companies with market capitalisation measured in billions.
The new investors are BVI-based Tanfield International Ltd. and Panama-based International Credit Bank. These corporations decided to purchase 16,666,666 shares of the common stock of Lake Oswego-based Calypte Biomedical, par value 3 cents, at a price 18 cents per share. Currently, the shares are sold at 21 cents per share.
In recent time, the future of Calypte Biomedical was undefined. In February, the American Stock Exchange intended to delist the company's stock. Now, the situation changed as the company raised 3 million USD.
Labels: BVI Companies
posted by Brian Obvi, Offshore Analyst | 3:41 PM
0 Comments:
Post a Comment
<< Home